Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (2)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge advises Active Biotech in connection with rights issue

 Vinge advises Active Biotech AB (publ) in connection with a rights issue of approximately SEK 43 million.
November 29, 2024

Vinge advises ABGSC and SEB in connection with Europi’s inaugural issuance of green bonds

Vinge has advised the joint arrangers in connection with Europi Property Group AB (publ)’s (the "Company") inaugural issue of EUR 50 million senior unsecured green bonds within a framework of up to EUR 100 million. The bonds carry a floating interest rate of EURIBOR 3M + 5.00% and have a tenor of three years. The Company intends to apply for admission to trading of the new bonds on Nasdaq Transfer Market and the sustainable bond list of Nasdaq Stockholm.
November 29, 2024

Vinge advises Rieber & Søn in connection with its acquisition of Accept Försäkringsaktiebolag (publ)

 Accept, with headquarter in Stockholm, has been an innovator in the Swedish insurance market since its formation in 1998. The company was the first with offering loss of income insurance and has since offered products that complement the general insurance offering. Today, Accept delivers web-based insurance solutions customised for its offering.
November 21, 2024